Predictors of clinical effectiveness of Hymenoptera venom immunotherapy

Clinical and Experimental Allergy

Volumn 44, Issue 5, 2014, Pages 736-746

  Rueff F ^a   Vos, B ^a,b   Oude Elberink, J ^b   Bender, A ^a   Chatelain, R ^a,c   Dugas Breit, S ^a   Horny, H P ^a   Kuchenhoff H ^a   Linhardt, A ^a   Mastnik, S ^a   Sotlar, K ^a   Stretz, E ^a   Vollrath, R ^a   Przybilla, B ^a   Flaig, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Allergy; Hymenoptera venom; Mastocytosis in the skin; Risk factors; Sting challenge; Tryptase; Venom dose; Venom immunotherapy

Indexed keywords

ALUTARD; ANTIHYPERTENSIVE AGENT; ANTISERUM; AQUAGEN; BEE VENOM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOSIDE; HYMENOPTERA VENOM; INSECT VENOM; PHARMALGEN; TRYPTASE; UNCLASSIFIED DRUG; WASP VENOM; ALLERGEN; VENOM;

ADULT; ALGORITHM; ALLERGIC REACTION; ALLERGY; ANESTHESIST; APIS MELLIFERA; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL INDICATOR; CLINICAL PROTOCOL; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HONEYBEE; HUMAN; HYMENOPTERA VENOM ALLERGY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MASTOCYTOSIS; MEDICAL HISTORY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR; SKIN BIOPSY; SKIN EXAMINATION; SYSTEMIC MASTOCYTOSIS; TREATMENT DURATION; TREATMENT FAILURE; VENOM IMMUNOTHERAPY; VESPULA; AGED; ANAPHYLAXIS; ANIMAL; BLOOD; DESENSITIZATION; HYMENOPTERA; IMMUNOLOGY; INSECT BITE; MIDDLE AGED; PROGNOSIS; RISK; SEVERITY OF ILLNESS INDEX; SKIN TEST; TREATMENT OUTCOME; URTICARIA PIGMENTOSA; BEE STING; DRUG TREATMENT FAILURE; OBSERVATIONAL STUDY; WASP STING;

ADULT; AGED; ALLERGENS; ANAPHYLAXIS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYMENOPTERA; INSECT BITES AND STINGS; MALE; MASTOCYTOSIS, CUTANEOUS; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN TESTS; TREATMENT FAILURE; TREATMENT OUTCOME; TRYPTASES; VENOMS;

EID: 84895530556     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12275     Document Type: Article

References (38)

1. Hockenhull J, Elremeli M, Cherry MG et al. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. Health Technol Assess 2012; 16:III-IV:1-110.
2. Golden DB, Moffitt J, Nicklas RA et al.; Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma & Immunology (AAAAI); American College of Allergy, Asthma & Immunology (ACAAI); Joint Council of Allergy, Asthma and Immunology. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852-4.
3. Bonifazi F, Jutel M, Biló BM, Birnbaum J, Müller U; EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70.
4. Krishna MT, Ewan PW, Diwakar L et al.; British Society for Allergy and Clinical Immunology. Diagnosis and management of hymenoptera venom allergy: British society for allergy and clinical immunology (BSACI) guidelines. Clin Exp Allergy 2011; 41:1201-20.
5. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64:1237-45.
6. Berezowska S, Flaig MJ, Ruëff F et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol 2014; 27:19-29.
7. Valent P, Akin C, Arock M et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157:215-25.
8. Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010; 10:347-53.
9. Valent P, Horny HP, Triggiani M, Arock M. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol 2011; 156:119-27.
10. González-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy 2011; 3:637-51.
11. Ruëff F, Przybilla B, Biló MB et al. Clinical effectiveness of venom immunotherapy for Hymenoptera venom allergy: A prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PLoS ONE 2013; 8:e63233.
12. Ruëff F, Przybilla B, Müller U, Mosbech H. The sting challenge test in Hymenoptera venom allergy. Position paper of the subcommittee on insect venom allergy of the European academy of allergology and clinical immunology. Allergy 1996; 51:216-25.
13. Ruëff F, Przybilla B, Biló MB et al.; European Academy of Allergy and Clinical Immunology Interest Group. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010; 126:105-11.
14. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1:466-9.
15. Ruëff F, Przybilla B, Biló MB et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. J Allergy Clin Immunol 2009; 124:1047-54.
16. Dugas-Breit S, Przybilla B, Dugas M et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010; 40:643-9.
17. Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 2001; 357:361-2.
18. Ruëff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6:284-8.
19. Ruëff F, Dugas-Breit S, Bauer C, Placzek M. Przybilla B [Mastocytosis - clinical picture and diagnosis]. Dtsch Med Wochenschr 2006; 131:1616-21.
20. Biló BM, Ruëff F, Mosbech H, Bonifazi FOude-Elberink JN; the EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60:1339-49.
21. Valent P, Akin C, Escribano L et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37:435-53.
22. Valent P, Horny HP, Escribano L et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603-25.
23. Wood SN. Generalized additive models. Boca Raton: Chapman & Hall, 2006:145-220.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974; 19:716.
25. Blum S, Gunzinger A, Müller UR, Helbling A. Influence of total and specific IgE, serum tryptase, and age on severity of allergic reactions to Hymenoptera stings. Allergy 2011; 66:222-8.
26. Bonadonna P, Perbellini O, Passalacqua G et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123:680-6.
27. Kucharewicz I, Bodzenta-Lukaszyk A, Szymanski W, Mroczko B, Szmitkowski M. Basal serum tryptase level correlates with severity of hymenoptera sting and age. J Investig Allergol Clin Immunol 2007; 17:65-9.
28. Haeberli G, Brönnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003; 33:1216-20.
29. Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108:1027-32.
30. Golden DB, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981; 67:370-4.
31. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529-35.
32. Bousquet J, Ménardo JL, Velasquez G, Michel FB. Systemic reactions during maintenance immunotherapy with honey bee venom. Ann Allergy 1988; 61:63-8.
33. Hamilton RG. Diagnosis and treatment of allergy to hymenoptera venoms. Curr Opin Allergy Clin Immunol 2010; 10:323-9.
34. Maurer M, Bader M, Bas M et al. New topics in bradykinin research. Allergy 2011; 66:1397-406.
35. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114:371-6.
36. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012; 130:698-704.
37. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998; 101:298-305.
38. González de Olano D, Alvarez-Twose I, Esteban-López MI et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008; 121:519-26.